Experience. Commitment. Results.
Mirati Therapeutics, Inc. (Nasdaq: MRTX), relating to its proposed sale to Bristol Myers Squibb. Under the terms of the agreement, MRTX shareholders will receive $58.00 and one CVR worth up to $12.00 in cash per share they own.
CapStar Financial Holdings, Inc. (Nasdaq: CSTR), relating to its proposed sale to Old National Bancorp. Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own.
PCTEL, Inc. (Nasdaq: PCTI), relating to its proposed sale to Amphenol Corp. Under the terms of the agreement, PCTI shareholders will receive $7.00 in cash per share they own
Consolidated Communications Holdings, Inc. (Nasdaq: CNSL), relating to its proposed sale to affiliates of Searchlight Capital Partners, L.P. and British Columbia Investment Management Corp. Under the terms of the agreement, CNSL shareholders are expected to receive $4.70 in cash per share they own.
Olink Holding AB. (Nasdaq: OLK), relating to its proposed sale to Thermo Fisher Scientific Inc. Under the terms of the tender offer, OLK shareholders will receive $26.00 in cash per share they own.
Startek, Inc. (NYSE: SRT), relating to its proposed sale to Capital Square Partners. Under the terms of the agreement, SRT shareholders will receive $4.30 in cash per share they own.
POINT Biopharma Global, Inc. (Nasdaq: PNT), relating to its proposed sale to Eli Lilly. Under the terms of the agreement, PNT shareholders will receive $12.50 in cash per share they own.
Orchard Therapeutics plc. (Nasdaq: ORTX), relating to its proposed sale to Kyowa Kirin Co. Under the terms of the agreement, ORTX shareholders are expected to receive $16.00 and one CVR worth $1.00 in cash per American Depositary Share they own.
SP Plus Corp. (Nasdaq: SP), relating to its proposed sale to Metropolis Technologies, Inc. Under the terms of the agreement, SP shareholders will receive $54.00 in cash per share they own.
SomaLogic, Inc. (Nasdaq: SLGC), relating to its proposed sale to Standard BioTools Inc. Under the terms of the agreement, SLGC shareholders will receive 1.11 shares of Standard BioTools per share they own